An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to ...

Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application ...

The immunotherapy combination was initially more costly but resulted in a lower cost of care over a 2-year period, investigators found. The immunotherapy combination of nivolumab (Opdivo) and ...

Please provide your email address to receive an email when new articles are posted on . The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%.

Discover comprehensive details about Ipilimumab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small ...

A Prescription Drug User Fee Act target date of April 21, 2025 has been assigned to the application. Findings showed the immunotherapy combination significantly improved overall survival (OS; primary ...